»ó´Ü¿©¹é
±â»ç (Àüü 393°Ç)
[Sub Story] Ç×°íÇ÷¾ÐÁ¦ 1Â÷Ä¡·á: RAAS ¾ïÁ¦Á¦ THE MOST 2018-11-08 14:29
[Sub Story] Ç×°íÇ÷¾ÐÁ¦ 1Â÷Ä¡·á: Ä®½·±æÇ×Á¦ THE MOST 2018-11-08 14:23
[Sub Story] Ç×°íÇ÷¾ÐÁ¦ 1Â÷Ä¡·á: ÀÌ´¢Á¦ THE MOST 2018-11-08 14:16
[Sub Story] ´ç´¢º´ ȯÀÚÀÇ Ç÷¾ÐÄ¡·á THE MOST 2018-11-08 14:10
[Sub Story] ½ÅÀåÁúȯ ȯÀÚ¿¡¼­ Ç÷¾ÐÄ¡·á THE MOST 2018-11-08 14:02
¶óÀÎ
[Drug Review] Àû±ØÀû Ç÷¾ÐÁ¶Àý Æз¯´ÙÀÓ ¼Ó ºÎ°¢µÇ´Â 3Á¦ º¹ÇÕÁ¦ ÀÓ¼¼Çü ±âÀÚ 2018-11-08 13:43
[Drug Review] ½Ã³×Ãò¶ó, ±â°üÁö Áõ»ó°ü¸® ³Ñ¾î Ç×¹ÙÀÌ·¯½º È¿°ú¿¡µµ ÁÖ¸ñ ÀÓ¼¼Çü ±âÀÚ 2018-11-08 13:36
[Expert Opinion] ¸¸¼ºÄáÆϺ´ ȯÀÚ¿¡¼­ ASCVD À§Çè°ü¸®: ARB/Statin ´ÜÀϺ¹ÇÕÁ¦ÀÇ ¿ªÇÒ ÆíÁýºÎ 2018-11-08 13:31
[Conference Report] ±âÀü ´Ù¸¥ °­·Â¡¤Áö¼Ó Ç÷¾Ð°­ÇÏÁ¦ Çϳª·Î ¹¶Ä¡¸é ÀÌ»óµ· ±âÀÚ 2018-11-08 13:24
[Conference Report] ¡°º¹ÇÕÁ¦ ¿ä¹ýÀ¸·Î ȯÀÚ ¼øÀÀµµ ³ô¿©¾ß ½ÉÇ÷°ü ÀÓ»óÇýÅá衱 ÆíÁýºÎ 2018-11-08 13:16
¶óÀÎ
[Conference Report] ±¹³» ¸®¾ó¿ùµå¼­ Åڹ̻縣ź/S-¾Ï·ÎµðÇÉ È¿°ú È®ÀÎ ÀÓ¼¼Çü ±âÀÚ 2018-11-08 13:08
[Conference Report] ÇǸ¶»ìźÀÇ ¶Ù¾î³­ Ç÷¾Ð°­ÇÏ È¿°ú, ISH 2018¿¡¼­ ºÎ°¢ ÀÓ¼¼Çü ±âÀÚ 2018-11-08 11:49
[Conference Report] ±¹³» DPP-4 ¾ïÁ¦Á¦ ¿¡º¸±Û¸³Æ¾, Á¦2Çü ´ç´¢º´ ÃʱâÄ¡·á À¯¿ë¼º È®ÀÎ ÆíÁýºÎ 2018-11-08 11:44
[Conference Report] ¾ËÃ÷ÇÏÀ̸Ӻ´ Áø´Ü¡¤°ü¸® À§ÇÑ 20°³ ±Ç°í»çÇ× Á¦½Ã ÀÓ¼¼Çü ±âÀÚ 2018-11-01 18:35
[Sub Story] ¾à¹°¿ä¹ý°ú Á¤½ÅÇÐÀû Ä¡·á ÀûÀýÇÑ º´¿ë ÁÖ¹® ÀÓ¼¼Çü ±âÀÚ 2018-11-01 18:06
¶óÀÎ
[Interview] ¡°Ä¡¸Å, ȯÀÚ°ü¸®µµ ÁÁÁö¸¸ ¿¹¹æ¿¡ ÁÖ·ÂÇؾߡ± ÀÓ¼¼Çü ±âÀÚ 2018-11-01 14:23
[Deep in Guideline] ¾à¹°°³¼ö ÁÙÀÎ º¹ÇÕÁ¦ Àü·«À¸·Î Ç÷¾ÐÁ¶Àý °­Á¶ ÀÓ¼¼Çü ±âÀÚ 2018-10-10 17:13
[Sub Story] HDL-C ¾à¹° ÇöÁÖ¼Ò´Â? ÀÌ»óµ· ±âÀÚ 2018-09-04 15:31
[Sub Story] CCB/ARB/½ºÅ¸Æ¾ º¹ÇÕÁ¦ ¾ÈÁ¤Àû ¡®ASCVD °ü¸®¡¯ ÀüȯÁ¡ ÀÓ¼¼Çü ±âÀÚ 2018-09-04 15:28
[Sub Story] ½ºÅ¸Æ¾°ú Ç×°íÇ÷¾ÐÁ¦ ½ÉÇ÷°üÁúȯ ¸Â¼³ ´ÜÀÏÆÀ ²Ù¸°´Ù ÀÌ»óµ· ±âÀÚ 2018-09-04 15:13
Back to Top